Latest Insider Transactions at Jazz Pharmaceuticals PLC (JAZZ)
This section provides a real-time view of insider transactions for Jazz Pharmaceuticals PLC (JAZZ). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Jazz Pharmaceuticals plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Jazz Pharmaceuticals plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 08
2025
|
Kenneth W O'Keefe Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,805
-5.92%
|
$200,355
$111.25 P/Share
|
|
Aug 08
2025
|
Patrick G Enright Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,805
-6.4%
|
$200,355
$111.25 P/Share
|
|
Aug 08
2025
|
Jennifer E. Cook Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,805
-14.28%
|
$200,355
$111.25 P/Share
|
|
Aug 08
2025
|
Heather Ann Mc Sharry Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,959
-8.74%
|
$217,449
$111.25 P/Share
|
|
Aug 08
2025
|
Patrick Kennedy Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,959
-22.62%
|
$217,449
$111.25 P/Share
|
|
Aug 08
2025
|
Laura Hamill Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,805
-20.66%
|
$200,355
$111.25 P/Share
|
|
Aug 08
2025
|
Mark Douglas Smith Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,805
-14.28%
|
$200,355
$111.25 P/Share
|
|
Aug 08
2025
|
Norbert G Riedel Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,805
-20.44%
|
$200,355
$111.25 P/Share
|
|
Aug 08
2025
|
Anne O Riordan Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,805
-9.86%
|
$200,355
$111.25 P/Share
|
|
Aug 08
2025
|
Rick E Winningham Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,805
-11.14%
|
$200,355
$111.25 P/Share
|
|
Aug 07
2025
|
Kenneth W O'Keefe Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,507
+10.32%
|
-
|
|
Aug 07
2025
|
Patrick G Enright Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,507
+11.07%
|
-
|
|
Aug 07
2025
|
Jennifer E. Cook Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,507
+21.72%
|
-
|
|
Aug 07
2025
|
Heather Ann Mc Sharry Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,507
+13.53%
|
-
|
|
Aug 07
2025
|
Patrick Kennedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,507
+28.82%
|
-
|
|
Aug 07
2025
|
Laura Hamill Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,507
+28.64%
|
-
|
|
Aug 07
2025
|
Mark Douglas Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,507
+21.72%
|
-
|
|
Aug 07
2025
|
Norbert G Riedel Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,507
+28.43%
|
-
|
|
Aug 07
2025
|
Anne O Riordan Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,507
+16.08%
|
-
|
|
Aug 07
2025
|
Renee D Gala President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
18,808
+14.85%
|
-
|
|
Aug 07
2025
|
Seamus Mulligan Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,507
+0.3%
|
-
|
|
Aug 07
2025
|
Rick E Winningham Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,507
+17.8%
|
-
|
|
Aug 05
2025
|
Samantha Pearce EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
577
-1.39%
|
$66,932
$116.1 P/Share
|
|
Aug 01
2025
|
Bruce C Cozadd Chairman & CEO |
SELL
Open market or private sale
|
Direct |
1,000
-0.23%
|
$113,000
$113.21 P/Share
|
|
Jul 01
2025
|
Bruce C Cozadd Chairman & CEO |
SELL
Open market or private sale
|
Direct |
1,000
-0.11%
|
$107,000
$107.63 P/Share
|
|
Jun 03
2025
|
Bruce C Cozadd Chairman & CEO |
SELL
Open market or private sale
|
Direct |
500
-0.11%
|
$55,000
$110.0 P/Share
|
|
Jun 02
2025
|
Bruce C Cozadd Chairman & CEO |
SELL
Open market or private sale
|
Direct |
500
-0.11%
|
$53,500
$107.9 P/Share
|
|
May 12
2025
|
Seamus Mulligan Director |
BUY
Open market or private purchase
|
Indirect |
1,621
+1.57%
|
$166,963
$103.0 P/Share
|
|
May 09
2025
|
Seamus Mulligan Director |
BUY
Open market or private purchase
|
Indirect |
100,000
+22.08%
|
$9,800,000
$98.91 P/Share
|
|
May 02
2025
|
Bruce C Cozadd Chairman & CEO |
SELL
Open market or private sale
|
Direct |
500
-0.11%
|
$60,000
$120.0 P/Share
|
|
May 01
2025
|
Bruce C Cozadd Chairman & CEO |
SELL
Open market or private sale
|
Direct |
1,000
-0.23%
|
$116,000
$116.35 P/Share
|
|
Apr 01
2025
|
Bruce C Cozadd Chairman & CEO |
SELL
Open market or private sale
|
Direct |
1,500
-0.34%
|
$184,500
$123.75 P/Share
|
|
Mar 10
2025
|
Robert Iannone EVP, Global Head of R&D & CMO |
SELL
Open market or private sale
|
Direct |
2,403
-2.93%
|
$331,614
$138.41 P/Share
|
|
Mar 10
2025
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,140
-13.98%
|
$156,180
$137.81 P/Share
|
|
Mar 07
2025
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,333
-14.05%
|
$183,954
$138.23 P/Share
|
|
Mar 07
2025
|
Mary Elizabeth Henderson SVP, Technical Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
698
-2.94%
|
$96,324
$138.23 P/Share
|
|
Mar 07
2025
|
Robert Iannone EVP, Global Head of R&D & CMO |
SELL
Open market or private sale
|
Direct |
7,080
-4.03%
|
$984,120
$139.11 P/Share
|
|
Mar 05
2025
|
Samantha Pearce EVP, Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,905
-4.42%
|
$262,890
$138.95 P/Share
|
|
Mar 05
2025
|
Neena M Patil EVP & Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,088
-7.92%
|
$564,144
$138.95 P/Share
|
|
Mar 05
2025
|
Philip L Johnson EVP & Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,149
-2.24%
|
$158,562
$138.95 P/Share
|
|
Mar 05
2025
|
Renee D Gala President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,704
-6.03%
|
$787,152
$138.95 P/Share
|
|
Mar 05
2025
|
Robert Iannone EVP, Global Head of R&D & CMO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,239
-5.55%
|
$722,982
$138.95 P/Share
|
|
Mar 05
2025
|
Bruce C Cozadd Chairman & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,251
-4.79%
|
$3,070,638
$138.95 P/Share
|
|
Mar 03
2025
|
Bruce C Cozadd Chairman & CEO |
SELL
Open market or private sale
|
Direct |
6,500
-1.38%
|
$936,000
$144.25 P/Share
|
|
Feb 28
2025
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
773
-7.54%
|
$110,539
$143.29 P/Share
|
|
Feb 27
2025
|
Robert Iannone EVP, Global Head of R&D & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
26,577
+12.88%
|
-
|
|
Feb 27
2025
|
Mary Elizabeth Henderson SVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
9,244
+17.62%
|
-
|
|
Feb 27
2025
|
Samantha Pearce EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,719
+18.02%
|
-
|
|
Feb 27
2025
|
Renee D Gala President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
34,666
+16.33%
|
-
|
|
Feb 27
2025
|
Patricia Carr SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,889
+21.97%
|
-
|